Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Interventions
Web based survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
Completed Not applicable Interventional Results available

CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

NCT02566525
Conditions
Elective Cardiac Surgery
Interventions
CytoSorb
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Lexington, Kentucky • Baltimore, Maryland • Springfield, Massachusetts + 5 more
Conditions
Multiple Myeloma, Leukemia, MGUS, Monoclonal B-Cell Lymphocytosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Total body irradiation, Mycophenolate Mofetil, Tacrolimus 60, Tacrolimus 90, Tacrolimus 120, Bone marrow transplant
Drug · Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma
Interventions
SDX-101 (R-Etodolac)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Recruiting Not applicable Interventional

PRP for Sexual Function

NCT07920900
Conditions
Female Sexual Dysfunction, Sexual Dysfunction, Physiological
Interventions
Autologous Platelet-Rich Plasma (PRP) Injection, Sterile saline injection
Biological · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
Interventions
autologous hematopoietic stem cells added to planned CAR T
Biological
Lead sponsor
Joshua Sasine, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions
Itacitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma, Relapsed Hematologic Malignancy
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Completed No phase listed Observational

Therapeutic Plasma Exchange in MG

NCT01927692
Conditions
Myasthenia Gravis
Interventions
Skin biopsy, Single Fiber Electromyography
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Scottsdale, Arizona • Miami, Florida • Tampa, Florida + 11 more
Conditions
Multiple Myeloma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 23 more
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myeloma
Interventions
Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide
Drug
Lead sponsor
Joseph Tuscano
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
La Jolla, California • Orange, California • Sacramento, California
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Ixazomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
Interventions
Sargramostim, BB-MPI-03, Montanide
Drug
Lead sponsor
Benovus Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Platelet Rich Plasma on Photoaged Skin

NCT01372566
Conditions
Photoaging
Interventions
Harvest PRP Separation System, Sterile Saline injection
Device · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Stem Cell Transplant, CAR T-Cell Transplant, CAR T-Cell Therapy, Cellular Therapy, Hematopoietic Stem Cell Transplant, HSCT, Multiple Myeloma, Leukemia, Lymphoma
Interventions
Education
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

NCT01761565
Conditions
Plasma Concentrations
Interventions
Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Pembrolizumab
Biological
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California